RPG Life Sciences Limited (RPGLIFE.BO)
INR 2253.25
(1.76%)
INR 2253.25
(1.76%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.63 Billion INR | -43.29% |
| 2022 | 2.41 Billion INR | 12.42% |
| 2021 | 2.15 Billion INR | 12.67% |
| 2020 | 1.91 Billion INR | 0.41% |
| 2019 | 1.9 Billion INR | -2.28% |
| 2018 | 1.94 Billion INR | -0.85% |
| 2017 | 1.96 Billion INR | 17.37% |
| 2016 | 1.67 Billion INR | -3.28% |
| 2015 | 1.72 Billion INR | 13.87% |
| 2014 | 1.51 Billion INR | -3.59% |
| 2013 | 1.57 Billion INR | 14.1% |
| 2012 | 1.38 Billion INR | 7.1% |
| 2011 | 1.28 Billion INR | 13.74% |
| 2010 | 1.13 Billion INR | 25.08% |
| 2009 | 906.32 Million INR | 11.49% |
| 2008 | 812.9 Million INR | 14.95% |
| 2007 | 707.15 Million INR | 24.4% |
| 2006 | 568.44 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 386 Million INR | 17.86% |
| 2023 Q1 | 325.7 Million INR | -39.91% |
| 2023 Q2 | 757.8 Million INR | 132.67% |
| 2023 FY | 1.37 Billion INR | -43.29% |
| 2023 Q4 | 327.5 Million INR | -54.37% |
| 2023 Q3 | 717.7 Million INR | -5.29% |
| 2022 Q3 | 628.3 Million INR | -1.15% |
| 2022 Q4 | 542 Million INR | -13.74% |
| 2022 FY | 2.41 Billion INR | 12.42% |
| 2022 Q2 | 635.6 Million INR | 3.55% |
| 2022 Q1 | 613.8 Million INR | 35.05% |
| 2021 Q3 | 591.8 Million INR | 4.91% |
| 2021 FY | 2.15 Billion INR | 12.67% |
| 2021 Q4 | 454.5 Million INR | -23.2% |
| 2021 Q1 | 541.9 Million INR | 43.21% |
| 2021 Q2 | 564.1 Million INR | 4.1% |
| 2020 Q1 | 496.9 Million INR | 17.55% |
| 2020 FY | 1.91 Billion INR | 0.41% |
| 2020 Q4 | 378.4 Million INR | -27.59% |
| 2020 Q3 | 522.6 Million INR | 1.99% |
| 2020 Q2 | 512.4 Million INR | 3.12% |
| 2019 Q2 | 536.3 Million INR | 7.52% |
| 2019 FY | 1.9 Billion INR | -2.28% |
| 2019 Q1 | 498.8 Million INR | 39.49% |
| 2019 Q4 | 422.7 Million INR | -18.3% |
| 2019 Q3 | 517.4 Million INR | -3.52% |
| 2018 Q4 | 357.6 Million INR | -33.11% |
| 2018 FY | 1.94 Billion INR | -0.85% |
| 2018 Q3 | 534.6 Million INR | -0.34% |
| 2018 Q2 | 536.4 Million INR | 3.35% |
| 2018 Q1 | 519 Million INR | 1.63% |
| 2017 FY | 1.96 Billion INR | 17.37% |
| 2017 Q4 | 510.7 Million INR | -5.25% |
| 2017 Q3 | 539 Million INR | 7.67% |
| 2017 Q2 | 500.6 Million INR | -2.09% |
| 2017 Q1 | 511.3 Million INR | 13.7% |
| 2016 Q1 | 419.6 Million INR | -4.64% |
| 2016 FY | 1.67 Billion INR | -3.28% |
| 2016 Q3 | 423.3 Million INR | -4.96% |
| 2016 Q2 | 445.4 Million INR | 6.15% |
| 2016 Q4 | 449.7 Million INR | 6.24% |
| 2015 Q2 | 419 Million INR | 4.96% |
| 2015 Q1 | 399.2 Million INR | -3.22% |
| 2015 FY | 1.72 Billion INR | 13.87% |
| 2015 Q3 | 440.6 Million INR | 5.16% |
| 2015 Q4 | 440 Million INR | -0.14% |
| 2014 Q4 | 412.5 Million INR | 16.49% |
| 2014 FY | 1.51 Billion INR | -3.59% |
| 2014 Q1 | 353.1 Million INR | -3.74% |
| 2014 Q2 | 429.6 Million INR | 21.67% |
| 2014 Q3 | 354.1 Million INR | -17.57% |
| 2013 Q2 | 407.5 Million INR | 9.04% |
| 2013 FY | 1.57 Billion INR | 14.1% |
| 2013 Q4 | 366.8 Million INR | -13.78% |
| 2013 Q3 | 425.4 Million INR | 4.39% |
| 2013 Q1 | 373.7 Million INR | 5.8% |
| 2012 FY | 1.38 Billion INR | 7.1% |
| 2012 Q2 | 362.1 Million INR | 12.04% |
| 2012 Q1 | 323.2 Million INR | 0.0% |
| 2012 Q4 | 353.2 Million INR | 0.48% |
| 2012 Q3 | 351.5 Million INR | -2.93% |
| 2011 FY | 1.28 Billion INR | 13.74% |
| 2010 FY | 1.13 Billion INR | 25.08% |
| 2009 FY | 906.32 Million INR | 11.49% |
| 2008 FY | 812.9 Million INR | 14.95% |
| 2007 FY | 707.15 Million INR | 24.4% |
| 2006 FY | 568.44 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bajaj HealthCare Limited | 985.34 Million INR | -65.982% |
| Aarti Drugs Limited | 1.16 Billion INR | -40.088% |
| NATCO Pharma Limited | 10.05 Billion INR | 83.739% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 46.803% |
| Shilpa Medicare Limited | 2.18 Billion INR | 24.997% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -16.589% |
| Alkem Laboratories Limited | 32.83 Billion INR | 95.019% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 92.365% |
| Venus Remedies Limited | 1.91 Billion INR | 14.653% |
| Lasa Supergenerics Limited | 291.17 Million INR | -461.692% |
| Ind-Swift Limited | 946.56 Million INR | -72.782% |
| Hester Biosciences Limited | 908.84 Million INR | -79.955% |
| Indoco Remedies Limited | 4.74 Billion INR | 65.56% |
| Bal Pharma Limited | 389.89 Million INR | -319.477% |
| Hikal Limited | 2.48 Billion INR | 34.221% |
| Achyut Healthcare Limited | 1.6 Million INR | -101546.986% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 23.006% |
| Ajanta Pharma Limited | 30.46 Billion INR | 94.631% |
| Alpa Laboratories Limited | 156.14 Million INR | -947.41% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 37.106% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 95.832% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -9989.638% |
| Brooks Laboratories Limited | 51.18 Million INR | -3095.584% |
| Nectar Lifesciences Limited | 625.55 Million INR | -161.45% |
| Divi's Laboratories Limited | 14.17 Billion INR | 88.458% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 98.294% |
| Eris Lifesciences Limited | 4.94 Billion INR | 66.912% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 97.579% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 85.95% |
| Granules India Limited | 7.18 Billion INR | 77.229% |
| Gufic Biosciences Limited | 1.07 Billion INR | -51.757% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -48.844% |
| Ipca Laboratories Limited | 13.91 Billion INR | 88.246% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 88.685% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -3443.418% |
| Laurus Labs Limited | 3.01 Billion INR | 45.679% |
| Mankind Pharma Limited | 23.15 Billion INR | 92.936% |
| Medicamen Biotech Limited | 335.16 Million INR | -387.966% |
| Medico Remedies Limited | 161.84 Million INR | -910.541% |
| Megasoft Limited | 49.52 Million INR | -3202.173% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 45.4% |
| Piramal Pharma Limited | 19.91 Billion INR | 91.787% |
| Sequent Scientific Limited | 2.9 Billion INR | 43.639% |
| Sigachi Industries Limited | 579.88 Million INR | -182.038% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 64.288% |
| Strides Pharma Science Limited | 9.16 Billion INR | 82.15% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 98.939% |
| Themis Medicare Limited | 782.85 Million INR | -108.915% |
| Unichem Laboratories Limited | 6.72 Billion INR | 75.683% |
| Wanbury Limited | 1.16 Billion INR | -40.879% |
| Windlas Biotech Limited | 1 Billion INR | -62.492% |
| Wockhardt Limited | 6.4 Billion INR | 74.445% |
| ZIM Laboratories Limited | 1.01 Billion INR | -61.442% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -15.239% |
| Suven Life Sciences Limited | 109.75 Million INR | -1390.205% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -48.819% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 89.694% |
| Lupin Limited | 95.67 Billion INR | 98.291% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 46.844% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -73.546% |
| Valiant Laboratories Limited | 36.28 Million INR | -4406.875% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 96.212% |
| FDC Limited | 5.34 Billion INR | 69.421% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 80.569% |
| Novartis India Limited | 470.1 Million INR | -247.905% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -111.466% |
| Neuland Laboratories Limited | 2.92 Billion INR | 44.176% |
| Morepen Laboratories Limited | 1.98 Billion INR | 17.709% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -296.555% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -141.885% |